PYOMETRA IN THE QUEEN
To spay or not to spay?

Fiona Hollinshead and Natali Krekeler

Introduction

Pyometra is an acute or chronic suppurative inflammation of the uterine wall in intact queens. It is characterised by endometrial hyperplasia with cystic dilation of endometrial glands and accumulation of purulent exudate in the uterine lumen. The disease is most often observed in dioestrus or ‘pseudopregnancy’ in the queen, which is a phase of progesterone dominance that lasts approximately 40 days. The relatively long progesterone-dominated dioestrous phase occurs in queens that undergo ovulation (induced or spontaneous) and predisposes them to the development of cystic endometrial hyperplasia (CEH) and subse-

Incidence of feline pyometra

A recent study from Sweden reported that 2.2% of intact queens were diagnosed with pyometra by the age of 13 years. The incidence of pyometra is considered to be lower in queens than in bitches, as queens are induced ovulators. However, underestimation of disease incidence is likely because queens often do not express clinical signs to the same extent as seen in bitches. Furthermore, it seems that, despite being induced ovulators, spontaneous ovulation is not as uncommon in queens as originally thought. There have been various reports of spontaneous ovulation in the queen, with incidence ranging from 30% up to 87%. Despite many hypotheses, the underlying cause of spontaneous ovulation in the queen is still unknown, but may be influenced by breed, increasing age and parity. Recently, a breed predisposition has been reported, with Oriental purebred cats having a higher incidence of pyometra than domestic and random-bred cats. This has also been observed by the authors. Oriental purebred cats are additionally known to come into oestrus year-round and often have short interoestrus intervals (associated with overlapping follicular waves) compared with domestic shorthair and random-bred cats. Furthermore, Oriental queens have a higher incidence of spontaneous ovulation than other cats. Therefore, the uterus of Oriental queens is exposed to more frequent oestrogen priming and periods of high progesterone concentration. These two factors are hypothesised to contribute to the higher incidence of pyometra in young Oriental breed cats compared with other cats of similar age. In the aforementioned large Swedish retrospective study, the median age of diagnosis of pyometra in Oriental/exotic purebred queens (Sphynx, Siberian, Ocicat, Korat, Siamese, Ragdoll, Maine Coon and Bengal) was significantly lower (4 years; P < 0.05) than that reported for the general cat population (>7 years).2

Practical relevance: Pyometra is a commonly occurring uterine disease in cats that often leads to loss of breeding potential and, in some cases, can be life threatening. An increased incidence of pyometra in Oriental/exotic purebred queens compared with other cats is likely because queens are induced ovulators and prone to ovulate spontaneously or are induced to ovulate (mechanical stimulation or hormone induction). The disease is most often observed in dioestrus.

Clinical challenges: Queens with pyometra often go undiagnosed as there may be few or only very mild clinical signs and laboratory changes. For example, the classical sign of mucopurulent bloody vulvar discharge often goes unnoticed. Abdominal ultrasound is the best tool for diagnosis of pyometra and for monitoring response to therapy.

Patient group: Classically, middle-aged/older nulliparous intact queens present with pyometra. However, so-called ‘stump pyometra’ can occur if ovarian tissue is left behind during ovariohysterectomy or ovariohysterectomy (ovarian remnant syndrome). Queens treated with exogenous steroid hormones such as high doses of megestrol acetate or medroxyprogesterone acetate for oestrus prevention can also develop CEH and pyometra.

Evidence base: There has been little published to date on CEH, endometritis and pyometra in the queen and most of the currently available information has been extrapolated from studies carried out in the bitch. The queen and the bitch have very different reproductive physiology; thus, further research and investigation into the precise aetiopathogenesis of these disease processes of the uterus in the queen is warranted.

Audience: This review is aimed at clinicians working in small animal practice, especially those in countries where surgical sterilisation is not practised as commonly as in the United States, Canada or Australasia, and who will therefore see a greater proportion of intact queens.
quent pyometra caused by infection from bacteria ascending from the vagina. The most common bacterium involved in pyometra is *Escherichia coli*. Similar to the bitch, regardless of the underlying cause, the presence of progesterone (endogenous or exogenous in source) facilitates the development of pyometra.

The incidence of feline pyometra (see box on page 21) is not well documented.

**Pathogenesis and aetiology: what comes first?**

Cats are classified as seasonally polyoestrous, coming into oestrus between spring and early autumn with a seasonal anoestrus in winter (long-day breeders). The oestrous period or ‘call’ lasts 6–7 days. If ovulation (either induced or spontaneous) occurs but the queen does not become pregnant, there follows a period of progesterone secretion (from the corpus luteum) for approximately 40 days. This is the dioestrous phase (or so-called pseudopregnancy). Cats that undergo an anovulatory oestrus will have an interoestrus interval of about 8–10 days with baseline progesterone levels.

The pathogenesis of pyometra is incompletely understood – both in the bitch and the queen, but especially the queen being an induced ovulator. In the bitch, pyometra is currently believed to be multifactorial in origin. It is most likely similar in the queen. The aetiology is similar in the two species, with progesterone influence predisposing the uterus to ascending bacterial (most commonly *E coli*) infection.

Originally CEH and pyometra were defined as one disease entity. It was believed that repeated exposure of the endometrium to high concentrations of oestrogen during prooestrus and oestrus, followed by high concentrations of progesterone during the luteal phase (ie, dioestrous), led to the development of CEH (Figure 1). This, in turn, predisposed the uterus to secondary bacterial infection and development of pyometra. More recently, the question has been raised as to whether pyometra and CEH are actually two separate disease entities. Although the conditions have many similarities and can be found as related events, they also have the potential to occur de novo. Any stimulus or irritant in a progesterone-influenced uterus can lead to CEH, and thus the presence of CEH in pyometra could merely be the result of a uterine reaction to the bacterial infection. This could explain why we see pyometra in young cats, which are unlikely to have underlying uterine pathology such as CEH. In bitches, it is hypothesised that varying pathogenicity of *E coli* strains might be responsible for the development of CEH. No studies investigating the effects of bacterial pathogenicity in pyometra have been undertaken in cats.

**Pivotal role of progesterone**

Importantly, regardless of the underlying cause of pyometra, the presence of progesterone (exogenous or endogenous) is required for pyometra to occur. This was confirmed in a canine disease model where intrauterine inoculation of a pathogenic strain of *E coli* in oestrus or anoestrus did not result in pyometra but inoculation of the same strain in dioestrus did. No comparable studies have been published in the queen.

**What role do reproductive hormones play?**

The majority of queens affected by pyometra are presented with clinical signs within 4 weeks of the onset of the latest oestrus. Although there is no evidence that abnormal ovarian hormone concentrations are involved in the pathogenesis of pyometra in queens or bitches, it has been shown that progesterone is necessary to initiate CEH and that oestrogen potentiates the effect by upregulating the expression of progesterone receptors. Therefore, pyometra is believed to be facilitated by an oestrogenic phase that is followed by a relatively long non-pregnant progesterone-dominated phase (dioestrous caused by spontaneous or induced ovulation).

Leukocyte inhibition, decreased myometrial contractions and a closed cervix in the progesterone-influenced uterus facilitate bacterial growth in a non-gravid uterus from ascending infection. Progesterone also stimulates uterine stromal and glandular epithelial proliferation and increases uterine glandular secretions, which are an important source of nutrients for the early developing embryos/fetuses in pregnant queens. These effects are cumulative in spontaneously ovulating cats or cats that experience repeated matings that do not result in pregnancy. Thus, the risk of uterine disease may increase with each non-pregnant oestrous cycle, as the presence of fetuses is effectively protective against the development of pyometra.

---

*Copyright: Dr Stephanie N Simpson. Source: LORI*
ment of pyometra. This finding was first discovered by Dow who reported that nulliparous bitches with pyometra outnumbered multiparous bitches with pyometra by approximately 10-fold. A similar effect is thought to hold true for queens.

However, it has also been shown that progesterone exposure alone, without prior oestrogen priming, can lead to CEH in the queen. The theory that progesterone is critical for the development of pyometra is supported by the fact that the use of exogenous steroid hormones (progestins such as megestrol acetate [MA] or medroxyprogesterone acetate [MPA]) for contraceptive purposes has been shown to induce the disease in both bitches and queens. Another observation that supports the essential role of progesterone in the disease process, at least in the canine species, is that the incidence of pyometra is similar in ovariectomised and ovariohysterectomised bitches.

Which bacteria are commonly involved?

In most cases of pyometra, the bacteria isolated are uropathogenic *E. coli*. Other bacteria, mostly normal vaginal commensals such as *Staphylococcus aureus*, *Klebsiella* species, *Proteus* species and *Streptococcus* species, have also been reported in cases of pyometra. The uterus is presumed to become infected via ascent of faecal bacteria through the vagina during oestrus when the cervix is relaxed. It has been shown that *E coli* are capable of establishing an infection in very young healthy dogs, which are unlikely to have underlying CEH changes. This may be another explanation for cases of pyometra in young queens. It is hypothesised that bacteria enter the uterus during pro-oestrus and/or oestrus and act as a mucosal irritant, thus stimulating the development of CEH under the influence of progesterone during dioestrus.

Factors other than bacterial virulence are also likely involved in the pathophysiology of pyometra in the queen, such as deficiencies in the innate immune response and inheritance of susceptibility.

What is the evidence for a genetic predisposition?

Previously, no breed predisposition for pyometra in queens had been reported. However, a retrospective study carried out in Sweden found that Oriental purebred cats have a higher incidence of pyometra than other breeds, with the Sphynx breed having the highest incidence. Other breeds with a predisposition include the Siberian, Ocicat, Korat, Siamese, Ragdoll, Maine Coon and Bengal. Furthermore, in the authors’ experience there are families that have a higher incidence of pyometra. These related queens are often geographically isolated, suggesting a hereditary predisposition to pyometra.

Endometritis is inflammation of the endometrium. Aside from chronic infertility, clinical signs of endometritis are rarely seen in the bitch or queen. In bitches, an infectious agent(s) is a common underlying cause. However, little information has been published on endometritis in either the bitch or queen. This is mainly due to the difficulty in collecting uterine samples for investigation (e.g., cytology and bacteriology) using a non-invasive technique and without causing further pathology.

Due to these limitations, a trial of antibiotic therapy should be considered in young breeding queens that repeatedly fail to become pregnant despite correctly timed matings, and with any of the following history:

- Confirmation of ovulation by either blood progesterone assay or ovarian ultrasound;
- Mated to more than one unrelated proven male;
- No abnormalities detected on complete physical (including genital) examination;
- No abnormalities found after ultrasonography of the reproductive tract (uterus and ovaries);
- Neutrophils observed during cytological oestrus (ie, presence of 100% superficial or cornified epithelial cells [Figure 2]).

The most common infectious agents isolated in cases of endometritis are normal vaginal flora. Therefore, use of a broad spectrum antibiotic with good uterine penetration such as clindamycin (5.5 mg/kg PO q12h) or amoxicillin/clavulanic acid (12.5 mg/kg PO q12h) is recommended. Antibiotic therapy should be started during oestrus and continued for approximately 2–3 weeks. Abdominal ultrasound should be performed after breeding (16 days after ovulation) to determine if the queen is pregnant or if there is uterine pathology, as indicated, for example, by the presence of intraluminal fluid or hyperechogenicity of the endometrium. Antibiotics are discontinued if the queen is pregnant or if there is no evidence of infection or inflammation. Thereafter, ongoing monitoring of fetal viability with weekly ultrasound examinations is recommended until parturition.

If uterine fluid is present, either medical or surgical treatment is needed depending on the age and breeding value of the queen (see pages 27–30). If the queen is not pregnant but has evidence of cystic endometrial hyperplastic changes (see page 25) then aglepristone therapy to remove progesterone and its negative influences on a non-pregnant uterus may be beneficial to future fertility. In a valuable breeding queen, uterine biopsy for the diagnosis of endometritis (by bacterial culture and cytology) and/or CEH (by histopathology) could be performed at this time. It is important that the queen is treated with aglepristone immediately after the biopsy procedure to prevent the risk of a subsequent pyometra.
**Review / Pyometra in the queen**

### Diagnostic approach

**Signalment/history**
Risk factors for pyometra in queens include:
- **Age** Typically, middle-aged to older queens (>5–7 years) with a history of oestrus within the previous 4 weeks are affected (although pyometra can be seen in younger queens, Table 1);
- **Breed** Orientals and purebreeds (ie, Siberian, Ocicat, Korat, Siamese, Ragdoll, Maine Coon, Burmese, Birman and Bengal) are predisposed;
- **Drug therapy** A history of treatment with progestins for prevention of oestrus (particularly high-dose regimens of MA [>0.2 mg/kg q24h] or MPA [>0.05 mg/kg q24h] for durations >1 year, especially in older queens), or pharmacological agents to induce ovulation (eg, human chorionic gonadotropin, gonadotropin-releasing hormone [GnRH]), increases the risk.

**Clinical presentation**
Presenting complaints include, but are not limited to, haemopurulent vulvar discharge (if the cervix is patent), depression, listlessness, lethargy, hyporexia/anorexia, vomiting and weight loss. Physical examination findings include abdominal distension, dehydration and pyrexia. Importantly, clinical signs are non-specific, with anorexia and lethargy being the most common presentations. Therefore, pyometra should be ruled out in any ill, intact queen. In contrast to pyometra in bitches, polyuria and polydipsia are not commonly seen in affected queens. Most importantly, clinical signs can be few or mild in queens with pyometra.

In many cases the uterus will be palpably enlarged but great care should be taken during abdominal palpation as it can result in uterine rupture if the cervix is closed and the uterus is friable. If the cervix is patent, the uterus may not be as enlarged and only a thickened uterine wall may be appreciated on palpation.

The presence of vulvar discharge is also dependent on the patency of the cervix. In open-cervix pyometra, a haemorrhagic, purulent vulvar discharge may be the only clinical sign. Cats can be fastidious with grooming, which is why a vulval discharge may not be noticed by owners, thereby delaying the diagnosis. Queens with closed-cervix pyometra may not show vulvar discharge and are more commonly systemically ill; absorption of bacterial toxins in these cats can result in endotoxaemia and sometimes bacteraemia.

### Laboratory findings
- **Haematology and biochemistry** Remarkably few haematological and biochemical changes are seen in queens with pyometra. The leukogram may show a marked neutrophilia (>35 x 10^9/L) with a left shift (± toxic changes) but this can be variable and, in some cases, the leukogram may be normal. It is not uncommon to have no other haematological disturbances in queens with pyometra. Hyperproteinanaemia, hypokalaemia, azotaemia and an elevation in liver enzymes (alanine aminotransferase and alkaline phosphatase), blood urea nitrogen and creatinine may be noted, especially if sepsis and dehydration are present. However, it is not uncommon to see only mild or no biochemical changes. Queens have significantly less evidence of renal damage associated with pyometra than bitches. In contrast to bitches, biochemical parameters are also not particularly helpful as predictors of disease outcome in queens with pyometra.

- **Serum progesterone** Progesterone concentration will commonly be elevated above 2 ng/ml, depending on the length of time since ovulation. If queens are diagnosed with pyometra towards the end of dioestrus, progesterone levels can be relatively low (0.5–2 ng/ml).

- **Cytology** Cytological examination of the vulvar discharge is likely to reveal degenerate polymorphonuclear cells and phagocytosed bacteria (Figure 3).

### Culture and sensitivity
Bacterial culture of vulvar discharge is not particularly helpful in confirming a diagnosis as normal vaginal flora is most likely to be isolated. However, sensitivity testing is important for making therapeutic decisions as some bacterial strains cannot be isolated from the uterine discharge. Bacterial culture and sensitivity results are available, therapy can be modified if needed.

---

**Figure 3** Cytological smear prepared from a queen with pyometra. Note the presence of degenerate neutrophils, epithelial cells and bacteria in the background. Differential interference contrast microscopy, oil immersion, x 1000

**Pyometra should be ruled out in any ill, intact queen. Clinical signs are non-specific, with anorexia and lethargy being the most common presentations.**
Imaging

Changes that are observed on abdominal radiography of a queen with pyometra include a distended uterus, which can lead to displacement of the small intestine (Figure 4). These changes are very similar to those seen in early pregnancy prior to fetal skeletal ossification (which starts approximately 40 days after the luteinising hormone [LH] peak). Also, it is often difficult to differentiate pyometra from other causes of uterine enlargement, such as mucometra, hydrometra, hemometra or leiomyoma, which is a further limitation of radiographic examination.

Abdominal ultrasound is the most important diagnostic tool when pyometra is suspected. Early in the disease process, the uterine horns typically appear distended with hypoechoic to hyperechoic fluid, with or without flocculation (Figure 5a). The uterine wall often appears thickened with irregular edges and small hypoechoic areas consistent with cystic changes to the endometrial glands (Figure 5b). However, many queens will present more than 4 weeks after ovulation, and even late in the luteal phase or early anoestrus phase after the cervix has been open for days or weeks. In these cases, there may be no intraluminal fluid detectable and only a thickened uterine wall may be seen (Figure 6).

Pyometra can cause diffuse or segmental changes and there have even been occasional reports of pyometra in one uterine horn and a pregnancy in the other horn.
Histopathology

Grossly, the uterine horns of a queen with pyometra are usually distended with some degree of annular ring formation on the surface (Figure 7). Protuberant bands are seen on the endometrial surface, which correspond to the annular rings on the serosa. The endometrium of a uterus affected by pyometra is classically described as ‘cobblestone’ in appearance (Figures 1 and 8). The endometrial surface is usually covered by a malodorous, mucopurulent exudate, which can vary in volume (Figure 8).

Histologically, thickening of the uterine wall is caused by proliferation and dilation of endometrial glands, which occurs throughout the endometrium. These glands contain mucopurulent exudate with large numbers of polymorphonuclear leukocytes (Figure 9). Dense infiltration of neutrophils can also be seen in the superficial stroma under the surface of the endometrium. In some cases, there is evidence of chronic inflammation with infiltrations of predominantly plasma cells and histiocytes in the stroma around the dilated cystic glands.8,9

Table 1 Summary of clinical, laboratory and diagnostic imaging findings in feline pyometra

<table>
<thead>
<tr>
<th>Clinical presentation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signalment</td>
<td>Middle-aged to older queens (&gt;5–7 years of age)</td>
</tr>
<tr>
<td></td>
<td>Also young cats, those receiving exogenous hormone treatment and/or with a breed predisposition</td>
</tr>
<tr>
<td>Clinical signs</td>
<td>Vulvar discharge, depression, lethargy, pyrexia, inappetence, hyporexia/anorexia, vomiting</td>
</tr>
<tr>
<td></td>
<td>Often clinical signs are very mild or absent; clinical signs are generally non-specific</td>
</tr>
<tr>
<td>Laboratory findings</td>
<td>Complete blood count: White blood cell count &gt;35,000 cells/μl, neutrophilia with left shift ± toxic change</td>
</tr>
<tr>
<td></td>
<td>Leukogram may be normal</td>
</tr>
<tr>
<td></td>
<td>Serum biochemistry: Hyperproteininaemia, hyperglobulinaemia</td>
</tr>
<tr>
<td></td>
<td>Often only mild or no changes</td>
</tr>
<tr>
<td>Progesterone concentration</td>
<td>&gt;2 ng/ml</td>
</tr>
<tr>
<td></td>
<td>Can be &lt;2 ng/ml in anoestrus or at end of luteal period (poorer treatment prognosis)</td>
</tr>
<tr>
<td>Diagnostic imaging</td>
<td>Ultrasonography: Thick-walled distended tubular uterus filled with hypoechoic/hyperechoic fluid</td>
</tr>
<tr>
<td></td>
<td>Often cystic endometrial changes in the uterine wall; amount of intraluminal fluid depends on patency of cervix and time since ovulation</td>
</tr>
<tr>
<td></td>
<td>Radiography: Fluid-dense distended tubular uterus in the mid-abdomen</td>
</tr>
<tr>
<td></td>
<td>Consider other differentials such as pregnancy, mucometra, hemometra or hydrometra</td>
</tr>
</tbody>
</table>

Differential diagnosis

Other causes of uterine enlargement and/or vulvar discharge include:

- Mucometra, hemometra and hydrometra (these pathologies are not associated with systemic clinical signs and neutrophilia)
- Pregnancy (ruled out with ultrasonography 25 days after the LH peak or by radiography 40 days after the LH peak)
- Metritis, retained fetal membranes (clinical signs typically appear within the first few days postpartum)
- Vaginitis due to vaginal mass/foreign body/anatomical anomalies
**Treatment approach**

Pyometra can be treated surgically or medically and, in some cases, a combination of the two approaches may be the most effective and safest solution. For example, medical treatment of systemically unwell or older patients to assist with uterine emptying prior to surgery is appropriate to reduce the morbidity and mortality that can be associated with immediate surgical treatment. Medical treatment can allow surgery to be delayed until a time when the queen has been stabilised with intravenous (IV) fluid therapy and IV antibiotics and the anaesthetic risk reduced.

A proportion of pyometra cases in cats spontaneously resolve after the onset of endogenous luteolysis and subsequent cervical opening, which allows drainage before the development of any systemic illness.

**Surgical management**

Ovariohysterectomy with resection of the entire cervix is the treatment of choice in all queens not intended for breeding. Cats that present in poor condition need to have any acid–base derangements, arrhythmias, hypotension, shock, electrolyte abnormalities and dehydration corrected before undergoing anaesthesia. Fortunately, the majority of cats with pyometra are systemically well at presentation and are good anaesthetic and surgical candidates.

**Indications for surgical treatment**

- Queens without significant reproductive value or queens not intended for future breeding
- Emergency presentations such as uterine rupture or torsion concurrent with pyometra
- Older queens, particularly those with significant cystic and degenerative endometrial changes detected on ultrasound examination
- Pyometra that is refractory to medical treatment

Regardless of presentation, IV fluid therapy and IV antibiotics should be administered. Great care should always be taken in handling the uterus during surgery, as it is often very friable (Figures 7 and 10). Placement of saline-soaked laparotomy sponges in the abdomen is recommended to prevent contamination of the abdominal cavity with purulent material. Removal of the cervix in its entirety is performed in order to avoid leakage of purulent material into the abdomen and prevent the risk of a stump pyometra occurring (Figure 11) if some ovarian tissue is inadvertently left behind (ovarian remnant syndrome). Postoperative monitoring for signs of shock, dehydration, sepsis, electrolyte and acid–base imbalances, hypoproteinaemia, hypoglycaemia and anaemia is required for 24–48 h following surgery.
Medical management
When considering medical treatment of a pyometra, it is important to rule out any concurrent conditions such as peritonitis, kidney disease, reactive hepatitis or disseminated intravascular coagulation (DIC). A full clinical and ultrasound examination, as well as additional haematological and biochemistry assays, should be carried out before commencing treatment. All patients receiving medical treatment for pyometra need to be very carefully monitored and, if systemically well, can be treated as in-house ‘day patients’. However, patients that become unwell or require fluid therapy should be immediately hospitalised. Owners should also be informed of the risk of treatment failure and that, ultimately, surgery may be required.

The rationale for medical therapy is three-fold (see box below). Pharmacological options include prostaglandin F2α (PGF), dopamine agonists and progesterone receptor antagonists or antiprogestins (Table 2).

Prostaglandin F2α
Repeated doses of PGF result in luteolysis of the feline corpus luteum. The resultant reduction in progesterone concentrations promotes cervical relaxation and a reduction in uterine secretions. PGF also has ecbolic activity that facilitates drainage of purulent material from the uterus.

There are two forms of PGF: its natural form (dinoprost tromethamine [Lutalyse; Zoetis]) or synthetic derivatives (eg, cloprostenol). Neither form is registered for use in companion animals but both can be used off-label in queens. Cloprostenol has been associated with fewer side effects and requires fewer injections due to its longer half-life. However, natural PGF induces greater myometrial contractions and therefore faster evacuation of purulent material from the uterus.

Generally, medical treatment is indicated for natural PGF (Lutalyse)

Recommended ‘low dose protocol’ for natural PGF (Lutalyse)

Start with 10–15 μg/kg SC q6h for the first day
Increase to 25 μg/kg q6h SC for day 2 (and day 3 if tolerance to PGF is low)
Increase to 50 μg/kg q8h SC for the next 3–5 days or until vulvar discharge is no longer observed or no fluid is detected in the uterus on ultrasound examination

‘Low dose protocol’ is a term now used by reproduction specialists for treatment with PGF. The protocol can be used on its own or, ideally, in combination with dopamine agonists (eg, cabergoline) or progesterone receptor antagonists (eg, aglepristone).

It is important to note that the corpus luteum in the queen is more resistant to the luteolytic effects of PGF than that of the bitch. Furthermore, if treatment is started soon after ovulation, the corpus luteum can be refractory to the effects of PGF. Often, higher doses of PGF for longer durations are required to obtain resolution of pyometra, especially if the diagnosis is made early in dioestrus (before day 20 postovulation). During this time, low doses of PGF are poorly effective in inducing complete and definitive luteolysis.

Side effects of PGF are dose-dependent and are rarely encountered with the ‘low dose protocol’, mostly limited to a transient hypersalivation. Individual variation in terms of tolerance of PGF is also seen, with some queens tolerating the drug well and requiring a more rapid dose increase. Tolerance of PGF and reduction of side effects is also typically seen after subsequent injections. Reported side effects include tachypnoea, vomiting, diarrhoea, urination and restlessness. Side effects appear about 20 mins after treatment and only last 15–30 mins. Patients should therefore be hospitalised for at least 1 h after treatment to observe for side effects. Systemically well

Generally, medical treatment is indicated for young healthy queens (<3 years old) that are intended for breeding.

Rationale for medical treatment
- Removal of progesterone, thus allowing cervical opening and improvement of local immune status
- Promotion of drainage of purulent material from the uterus and elimination of bacteria through an open cervix, aided by induction of myometrial contractions
- Prevention of further bacterial proliferation and release of endotoxins

order to minimise the ecbolic effect of the drug and to reduce the risk of uterine rupture, as well as to reduce the side effects associated with higher doses of PGF. Once luteolysis has occurred and the cervix opens, the dose can be increased depending on the individual’s tolerance of the PGF. Doses greater than 50 μg/kg should not be required, which is significantly less than the 200–250 μg/kg reported in the older literature.
queens can be managed as ‘day patients’ – receiving injections throughout the day while under veterinary supervision but able to go home overnight when no medication is given.

**Dopamine agonists**
Dopamine agonists can be used for the treatment of pyometra in the queen either alone or in combination with PGF or a progesterone receptor antagonist (see below). Dopamine agonists are ergot-derived alkaloid compounds that act as prolactin antagonists and thus have anti-luteotrophic activity. They are effective from approximately 15–20 days after ovulation when prolactin is present. Therefore, if a queen presents with pyometra soon after oestrus, anti-prolactin agents are preferred over PGF as they are very effective at inducing luteal arrest and luteolysis in early dioestrus. However, if a queen presents more than 4 weeks after oestrus or mating, use of a dopamine agonist in combination with PGF potentiates the luteolytic effect, causing more rapid luteolysis and leading to cervical opening within 24–48 h.

There are two commonly used dopamine agonists: cabergoline and bromocriptine. Cabergoline is associated with few or no side effects and involves only once daily administration, whereas bromocriptine has a number of side effects including vomiting, anorexia, depression and some behavioural changes, and also requires administration two to three times a day. The recommended dose of cabergoline is 5 µg/kg PO q24h; the dose of bromocriptine is 10–25 µg/kg PO q8h. Both drugs are most commonly used in combination with PGF, with the duration of treatment usually being 7 days.

**Progesterone receptor antagonists or antiprogestins**
Progesterone receptor antagonists or antiprogestins, such as aglepristone (Alizine; Virbac), are synthetic steroids that competitively bind to progesterone receptors with a greater (9 x in cats) affinity than natural progesterone. This results in a decrease in progesterone activity. Aglepristone has minimal side effects and is a good choice for the treatment of closed-cervix pyometra as it results in cervical opening with minimal uterine contractions. It also induces luteolysis. However, queens that present with poor liver and/or kidney function should not be treated with aglepristone.

Aglepristone is most effective when used in combination with natural PGF (dinoprost) for 5–10 days to potentiate luteolysis and enhance uterine contractions. This is particularly important in cats as they are notoriously resistant to luteolysis and removal of the effects of progesterone on the uterus. Furthermore, initiation of aglepristone treatment 48 h before starting PGF treatment can reduce the risk of uterine rupture in a closed-cervix pyometra by slowly opening the cervix without the stimulation of strong uterine contractions. Therefore, when using PGF in combination with aglepristone, treatment with PGF should start on day 3; PGF is then given daily as per the ‘low dose protocol’ described on page 28, except on days when aglepristone is given.

The recommended dosage of aglepristone in the queen is 15 mg/kg SC twice, 24 h apart, and then a single injection on day 8. A higher dose rate is recommended for queens compared with bitches due to reduced bioavailability in the queen. Depending on the patient’s condition, additional injections of aglepristone can be given on days 14 and 28 if resolution of the pyometra has not occurred. In these chronic cases, treatment with aglepristone weekly (mean duration of effect of aglepristone is 6 days) for 2 months has been reported. However, the prognosis with regard to fertility and recurrence rate is significantly poorer in these cases compared with cases that respond after the initial three injections on days 1, 2 and 8.

Treatment with aglepristone (15 mg/kg SC q24h) in combination with trimethoprim/sulfadoxine for 7 days resulted in a success rate of 90% (9 out of 10 cats). The authors did not note any recurrences for 2 years after treatment.

---

**Table 2 Dosages of commonly used luteolytic, anti-luteotrophic and antiprogestin drugs for treatment of feline pyometra**

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Dose</th>
<th>Protocol</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dinoprost (Lutalyse; Zoetis)</td>
<td>10 µg/kg SC</td>
<td>tid–5x/day = 5–7 days</td>
<td>Luteolysis</td>
</tr>
<tr>
<td></td>
<td>25 µg/kg SC</td>
<td>tid–5x/day = 5–7 days</td>
<td>Myometrial contractions</td>
</tr>
<tr>
<td></td>
<td>50 µg/kg SC</td>
<td>tid–5x/day = 5–7 days</td>
<td>Cervical opening</td>
</tr>
<tr>
<td></td>
<td></td>
<td>if used in combination</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>with aglepristone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>treatment is given</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>on days 3–7</td>
<td></td>
</tr>
<tr>
<td>Cloprostenol</td>
<td>1 µg/kg SC</td>
<td>sid for 5–7 days or until</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>until resolution</td>
<td></td>
</tr>
<tr>
<td>Cabergoline</td>
<td>5 µg/kg PO</td>
<td>sid</td>
<td>Anti-prolactin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anti-luteotrophic</td>
</tr>
<tr>
<td>Bromocriptine</td>
<td>10–25 µg/kg PO</td>
<td>tid</td>
<td></td>
</tr>
<tr>
<td>Aglepristone</td>
<td>15 mg/kg SC</td>
<td>Days 1, 2, 8 and weekly*</td>
<td>Progesterone receptor antagonist</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cervical opening</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Luteolysis</td>
</tr>
</tbody>
</table>

*Depending on response to treatment
SC = subcutaneous; PO = oral; sid = once a day; tid = three times a day; 5x/day = five times a day
Antimicrobial therapy

Antimicrobial therapy should be initiated immediately with a broad spectrum antibiotic. Culture and sensitivity testing should be performed but therapy has to be started at the time of diagnosis on the assumption that E. coli is the most likely pathogen. Excellent results have been achieved with amoxicillin/clavulanic acid (12.5–25 mg/kg PO q12h) or cephalosporins (eg, cefazolin 22 mg/kg IV or IM q8h) and potentiated sulfonamides; care should be taken in using cephalosporins or sulfonamides if renal function is impaired. If oral antibiotics are administered, care must be taken to give the drugs at a different time from the PGF, which might lead to vomiting.

Antimicrobial therapy should be continued for at least 14 days after resolution of vulvar discharge and evacuation of all fluid from the uterine lumen as determined by ultrasound examination.

Assessing the response to therapy and predicting future fertility

There are a number of parameters (see below) that should be assessed throughout the treatment of a queen with pyometra to monitor the response to treatment and determine when luteolytic treatment can cease, as well as to provide an indication of potential future fertility.

A clinical improvement is usually seen within 48 h of initiation of medical therapy. Ideally, resolution of all clinical signs should occur within 7–10 days.

Figure 12 Ultrasonogram of a uterine horn in a queen treated medically for pyometra several weeks earlier. Note that there is no intraluminal fluid present, but there are marked cystic changes in the thickened uterine wall, indicating a poor prognosis for future fertility. Courtesy of Dr Cheryl Lopate, Wilsonville Veterinary Clinic, USA

Monitoring tools

- **Ultrasound of the uterus** Ultrasound examination is the most important monitoring tool. A decrease in uterine size by 50% should be seen 72–96 h after initiation of therapy. If a reduction in uterine size of at least 50% is not observed after 5 days of treatment, the prognosis for future fertility is poor. In cases that respond poorly to luteolytic therapy, surgery is recommended to remove the fluid-filled uterus. In bitches, treatment for longer than 7–10 days can increase the risk of complications such as DIC. This has not been reported in the queen but should be a consideration when undertaking prolonged treatment. Weekly ultrasound examinations are recommended to assess the response to therapy. When the uterine dimensions have returned to normal and there is no fluid present in the uterus, luteolytic treatment can cease. Repeat ultrasound examination 2 weeks after resolution of clinical signs and treatment is advised to assess uterine health (eg, degree of CEH changes) and to confirm the absence of intraluminal fluid (Figure 12). This is especially important when treatment is started in a queen soon after ovulation or in the early luteal phase when the corpus luteum is more refractory to luteolysis and intrauterine fluid accumulation can recur. A reduction in the uterine wall thickness and often also in the degree of CEH changes may be detected on ultrasound after removal of progesterone and resolution of bacterial infection.

- **Vulvar discharge** Vulvar discharge should increase in volume within the first 24 h of treatment and usually ceases about 5–7 days after the onset of treatment. However, in contrast to dogs, pyometra in cats is often
The prognosis for survival is good with immediate medical or surgical treatment, provided uterine rupture has not occurred. If uterine rupture occurs, the mortality rate is high (30–50%). Overall, the mortality rate for queens with pyometra has been reported to range from 5.6–8%. This relatively high rate may be related to the fact that affected queens often show only very mild and non-specific clinical signs. Therefore, they may sometimes be misdiagnosed for a period of time or presented for veterinary attention late in the disease process; both scenarios result in a less favourable outcome.

Following medical treatment, the prognosis for future fertility and the risk of recurrence of pyometra depend on a number of factors, including the age and parity of the queen, the degree of CEH changes detected by ultrasound, and the time taken to respond to therapy and for the pyometra to resolve. Older (≥6 years) nulliparous queens with severe CEH changes detectable on ultrasound (Figure 12) that respond slowly to therapy and require protracted treatment (≥2 weeks) have a poor prognosis for preservation of fertility and are likely to develop recurrence of pyometra.

There is very little published data on pregnancy or recurrence rates in queens after treatment of pyometra. A substantial retrospective analysis of treatment and subsequent reproductive performance in queens treated medically for pyometra is needed. It is likely that, similar to bitches, there is high variability in pregnancy and recurrence rates after treatment. However, in the authors’ experience, the success rate for pregnancy and normal litter size after treatment for pyometra is high (pregnancy rate >80%) if:

- **Good case selection** for medical treatment is practised;
- i.e., young, healthy queens that do not have evidence of uterine pathology (e.g., CEH);
- **Effective treatment** is initiated immediately;
- **Close monitoring** during treatment is performed, and medical treatment is ceased when parameters being monitored are not improving in a timely manner;
- **Good breeding management** of subsequent heats (see below) is ensured.

Similarly, the risk of recurrence of pyometra at the subsequent oestrus is variable and depends on case selection and breeding management. Queens that do not respond to medical therapy quickly have a poor prognosis for return to fertility and an increased risk of pyometra at the next oestrus.

Queens with progesterone concentrations <2 ng/ml, or those that are in anoestrus, usually respond poorly to medical therapy.

### Management of breeding queens after medical treatment of pyometra

It is optimal that all queens intended for breeding are mated or inseminated on the first oestrus following treatment for pyometra, as a pregnant queen is significantly less likely to develop recurrence of pyometra. Therefore, it is important to manage the oestrus to optimise the likelihood of the queen becoming pregnant. Using a proven, fertile, young tom cat or, if AI is to be carried out, using high-quality fresh semen, is essential, as is optimal timing with the use of ovulation-inducing agents. Observation of multiple matings and confirmation of ovulation by using progesterone ≥2 ng/ml has occurred (indicated by serum progesterone <2 ng/ml). This is particularly valuable if PGF alone is used to treat the pyometra or in refractory cases to help determine whether complete luteolysis has occurred. Progesterone receptor antagonists displace the endogenous progesterone, thus elevating systemic levels initially. Therefore, when using this drug, progesterone concentrations must be interpreted with caution to assess luteolysis. The progesterone concentration 3 weeks after initiation of aglepristone treatment should be <2 ng/ml.

**Vaginal cytology**

The number of neutrophils seen on vaginal cytology should decrease over the course of treatment.

**Leukogram**

Weekly complete blood cell counts should be performed to evaluate neutrophilia. In most patients, the leukogram will return to normal 2–3 weeks after commencement of medical therapy.

**Serum progesterone**

Measurement of serum progesterone concentration prior to starting medical therapy can be helpful with regard to prognosis. Queens with low progesterone concentrations (<2 ng/ml) or those that are in anoestrus are poor candidates for medical therapy as they usually respond poorly. Measurement of progesterone at weekly intervals can help determine if luteolysis has occurred (indicated by serum progesterone <2 ng/ml). This is particularly valuable if PGF alone is used to treat the pyometra or in refractory cases to help determine whether complete luteolysis has occurred. Progesterone receptor antagonists displace the endogenous progesterone, thus elevating systemic levels initially. Therefore, when using this drug, progesterone concentrations must be interpreted with caution to assess luteolysis. The progesterone concentration 3 weeks after initiation of aglepristone treatment should be <2 ng/ml.

**Vaginal discharge**

The nature of the vaginal discharge will also gradually change – from purulent (and often blood-tinged) to serosanguineous, before eventually becoming sanguineous, before eventually becoming...
illness occur. An early ultrasound examination should be scheduled for 16 days after the LH peak to detect either embryonic vesicles (consistent with pregnancy) or uterine fluid (consistent with recurrence of pyometra).

However, it is often not possible to breed a queen on every oestrus subsequent to treatment for pyometra. Prevention of oestrus in these queens – especially individuals that are known repeatedly to spontaneously ovulate – is something to consider to reduce the risk of pyometra recurrence. Unfortunately, safe and effective methods and pharmaceutical agents for prevention of oestrus in queens are limited. GnRH analogues such as deslorelin implants (Suprelorin; Virbac) are reversible contraceptives that inhibit oestrus by downregulation of the hypothalamic–pituitary–ovarian axis.28 The effects are not only long term but highly variable. A minimum of 6 months’ suppression of oestrus would be obtained from a 4.7 mg implant and a minimum of 12 months from a 9.4 mg implant. The timing of implantation with regard to season would have an effect on this variability, as well as individual response. In one study, the period of oestrus suppression after implantation with a 4.7 mg Suprelorin implant in 20 female cats ranged from 16–37 months.29 Suprelorin is not registered for use in queens (or bitches) due to this variability in response. Importantly, in the above-mentioned study, 7/8 queens that were mated after the implant was no longer effective became pregnant and went on to kitten naturally.

Melatonin implants have been reported to safely provide oestrus suppression for up to 4 months in queens.30,31 Synthetic progestins have been widely used for oestrus suppression in the queen, especially in European countries.17 Great care should be taken when using these agents (eg, MA and MPA) in a queen that already has cystic changes in the uterus as this may predispose to recurrence of pyometra. Use of anabolic steroids such as mibolerone for oestrus prevention is contraindicated in cats.

An alternative management strategy for queens with a history of pyometra is to measure serum progesterone concentration 3–4 weeks after the end of oestrus to evaluate for spontaneous ovulation. If ovulation has occurred (indicated by progesterone concentrations >2–5 ng/ml), treatment with aglepristone in an attempt to prevent pyometra may be considered.

Queens no longer intended for breeding should undergo ovariohysterectomy. Ovariectomy is not recommended in a queen that has had pyometra and previous pregnancies, as the risk of a pyometra recurring in these queens is high if exogenous hormonal therapy (oestrogens and progestins) is administered or if ovarian remnants are inadvertently left behind after ovarioectomy.

**KEY POINTS**

- There are many published studies on the prevalence, pathophysiology, treatment and prognosis of pyometra in the bitch. Unfortunately this work has not yet been documented in queens and there has been much extrapolation from the bitch as a model for pyometra in the queen.

- A recent large retrospective study indicates that the incidence of pyometra in the queen is potentially much higher than initially assumed. This finding opens up many questions as to the underlying pathogenesis of pyometra in the queen.

- Queens are unique in that the corpus luteum is much more resistant to the currently available drugs and protocols available for the medical treatment and management of pyometra. More refractory cases are seen than in bitches and often a more aggressive approach is required to induce luteolysis.

- Successful medical treatment and, more importantly, successful breeding of a queen after treatment of a pyometra is ultimately influenced by the selection of suitable candidates for medical therapy.

- With the availability of new drugs and protocols for the treatment of pyometra in queens, as well as a greater understanding of appropriate selection of candidates for medical therapy, clinicians are now much more able to facilitate a successful decision by owners of queens that develop a pyometra in regard to ‘spay or not to spay?’.
Funding
The authors received no financial support for the research, authorship and/or publication of this article.

Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

References

Available online at jfms.com

Reprints and permission: sagepub.co.uk/journalsPermissions.nav
For reuse of images only, contact the corresponding author.